The 24th China Hi-Tech Fair Opens on November 15 in Shenzhen, China
15.11.2022 20:13:00 EET | Business Wire | Press release
The 24th China Hi-Tech Fair (CHTF 2022) kicked off in Shenzhen on November 15, 2022. Taking place until November 19, this year’s event has been comprehensively upgraded to the largest ever, integrating new product and technology launches, product and solution exhibitions, trade negotiations, and investment finance, across a diverse variety of hi-tech sectors including biomedicine, new materials, modern agriculture, fine chemicals, aerospace, new energy, high-end equipment manufacturing, energy conservation and environmental protection.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20221115006208/en/
International Pavilion and IT Exhibition of CHTF 2022 (Photo: Business Wire)
CHTF 2022 will gather a total of 5,000 exhibitors, including domestic multinationals and industry champions such as China General Nuclear Power Corporation, Huawei, ZTE, and Han’s Laser, along with hi-tech “little giants” such as: Kemai, a digital payment system provider; Keanda, a rail transit products manufacturer; and Insighters, a medical technology startup.
Also participating are overseas exhibitors from 38 countries including Brazil, Canada, Finland and Russia, some of which will join via CHTF 2022’s virtual platform. Among them, the Russian Ministry of Education and Technology and the Bavarian State Government of Germany, two of CHTF’s longstanding cooperation partners, have been sending delegations to CHTF for more than 20 consecutive years.
CHTF 2022 will host the inaugural Water Conservation and Innovation Exhibition, which together with a high-tech talent attraction show and an expo for emergency safety will boost the appeal of the event.
Meanwhile, the CHTF Hi-Tech Forum will be held on November 15-17, with a key focus on the digital economy, metaverse, quantum computing, AI, cloud computing, “lighthouse” factories and smart cities, future mobility, and “dual-carbon” goals. The forum will be livestreamed here.
The X-Lake Forum 2022, as the main side-forum of CHTF 2022, was held on November 15. Focused on “openness, integration and future”, this forum discussed development trends and shared cutting-edge hi-tech innovations. John Lee, Chief Executive of the Hong Kong Special Administrative Region; Ho Iat-seng, Chief Executive of the Macao Special Administrative Region; and Ciyong Zou, Director at UNIDO delivered video speeches. Scholars, academicians and renowned industry leaders including Nobel Laureate Roger D. Kornberg delivered keynote speeches at the forum.
More information is available on https://www.chtf.com/english/
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20221115006208/en/
Contact information
For exhibitor and visitor
Ms. XIE Yan, +8675582848652, selenaxie@chtf.com
Ms. WANG Peggie, +8675582848962, wangyq@chtf.com
Ms. CUI Can, +8675582848764, cathy_cui@chtf.com
Ms. YANG Dan, 86 755 8284 8695, yangd@chtf.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Zambon Announces European Commission Approval of Hopledo® for Adults with Parkinson's Disease and Moderate to Severe Motor Fluctuations28.8.2026 12:00:00 EEST | Press release
Zambon today announced that the European Commission (EC) has granted marketing authorization for Hopledo® (modified-release levodopa/carbidopa) for the treatment of adult patients with Parkinson’s disease and moderate to severe motor fluctuations who have not been sufficiently stabilized with oral levodopa/dopa decarboxylase (DDC) inhibitor-based treatment regimens. Zambon expects to begin the phased introduction of Hopledo® across European markets starting October 2026. The company is working closely with healthcare authorities and other stakeholders to support timely access for people with Parkinson’s disease who continue to experience moderate to severe motor fluctuations despite current oral therapies. Hopledo® is a first-in-class, oral, modified-release formulation of levodopa/carbidopa (LD/CD) approved for the treatment of motor fluctuations of Parkinson’s disease, the fastest growing neurological condition in the world according to the World Health Organization1. Despite availab
MTG-I2 Safely in Orbit, Unlocking Faster and Sharper Weather Monitoring Across Europe28.8.2026 11:16:00 EEST | Press release
The Meteosat Third Generation Imager 2 satellite (MTG-I2) has successfully passed its first critical post-launch milestones, completing the first full Meteosat Third Generation constellation in orbit. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260828243790/en/ Credit: Arianespace livestream The imager satellite MTG-I2 is safely in orbit and operating as expected following its successful launch yesterday at 22:11 CEST on board an Ariane 6 rocket from Europe’s Spaceport in French Guiana. Our teams have established communication with the spacecraft, which has also deployed its solar panels to ensure its autonomous production of energy. MTG-I2 is in perfect shape to start its Launch and Early Operations Phase that will bring it to a higher orbit, 36 000km above Earth over the following two weeks, where a longer period of calibration and validation of its instruments will begin. This summer’s extreme weather and wildfires hav
New Daiichi Sankyo Data Underscore the Effect of Bempedoic Acid in the Real-World Management of Dyslipidemia and Cardiovascular risk28.8.2026 11:00:00 EEST | Press release
Daiichi Sankyo (TSE:4568) today announced new results from the MILOS study that demonstrate the real-world impact of bempedoic acid administered either alone or as a fixed-dose combination with ezetimibe, in the management of dyslipidaemia. Presented at the European Society of Cardiology Congress 2026 in Munich, the findings show that the clinically relevant reductions in low-density lipoprotein cholesterol (LDL-C) achieved within the first year of treatment are estimated to translate into clinically meaningful reductions in 10-year cardiovascular (CV) risk.1 The data further reinforce the clinical value of bempedoic acid, and its fixed-dose combination with ezetimibe, across a diverse range of patient subtypes, regardless of gender and glycaemic profile (diabetes, pre-diabetes, or normoglycemia).2,3 Key findings from the new analyses of the MILOS study include: 10-year CV risk estimate reduction: An analysis of 960 at-risk patients estimated that one year of bempedoic acid-add-on ther
TVS Motor Company Appoints Peyman Kargar as Director and Chief Executive Officer28.8.2026 10:31:00 EEST | Press release
TVS Motor Company, part of TVS VENU and a leading global manufacturer of two and three-wheelers, today announced the appointment of Peyman Kargar as Director and Chief Executive Officer, effective January 27, 2027. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260827012301/en/ Peyman Kargar Peyman will succeed K. N. Radhakrishnan, who will continue in his role until then to ensure a seamless transition. Following the transition, Radhakrishnan will serve as Non-Executive Director up to the date of the ensuing AGM scheduled in July 2027. He has been a tremendous leader and played a pivotal role in the growth of TVS Motor Company. The leadership transition comes as TVS Motor Company builds on strong business performance and continues to consolidate its position in India and expand its global presence. In FY2025-26, the company achieved a record performance, selling 5.9 million vehicles globally and delivering 30% revenue growt
Philips and Imricor Launch Cardiac Interventional MR Lab Solution, Expanding Longstanding Collaboration27.8.2026 22:27:00 EEST | Press release
Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, and Imricor Medical Systems (ASX: IMR), a pioneer and world-leading developer of MR-compatible products for interventional MR procedures, today announced a new Interventional MR (iMR) lab solution for Philips 1.5T MR. The first commercially available configuration* combines Philips’ 1.5T MRI platform and Imricor's portfolio of iMR systems and consumables, enabling an MR-guided workflow for cardiac intervention, without compromising on MR field strength. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260827693715/en/ Meeting the need for greater tissue insight during cardiac intervention Cardiac arrhythmias affect millions of people worldwide, and catheter ablation is an established and increasingly utilized treatment for many complex cardiac arrhythmias. Yet today, these procedures continue to rely primarily on X-ray fluoroscopy, which provides only
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom